Lysosomal storage disorders - overview

Overview | Resources & tools

Successful management of lysosomal storage disorders requires specialization and focus. At Accredo, we go beyond standard pharmacy services, employing specialty-trained pharmacists and nurses with experience in lysosomal storage disorders and the therapies used to treat them. Our LSD-dedicated team provides comprehensive therapy support services to patients and physicians and can assist your office in providing the many administrative and clinical services involved with complex therapies.

Accredo is a leading provider of genetic disorder therapies in the United States. Our experience dates back to 1991, when we dispensed the first commercial prescription for Ceredase®, followed by the launch of its recombinant version, Cerezyme®, in 1994. Since then, we have expanded our portfolio to include access to the full line of enzyme replacement therapy products—with exclusive distribution rights to Cystadane®, Orfadin®, and Adagen®. We currently dispense therapies for the following lysosomal storage disorders:

• Fabry disease
• Gaucher disease
• Hunter syndrome (mucopolysaccharidosis II or MPS II)
• Hurler-Scheie (mucopolysaccharidosis I or MPS I)
• Mucopolysaccharidosis VI (MPS VI)
• Pompe disease
  
  If you have any questions regarding lysosomal storage disorders, please give us a call at 1 877 472.1326.